Status:
UNKNOWN
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation
Lead Sponsor:
Shaimaa Fawzy Abdel-rady Abdel-latif
Conditions:
Non-segmental Vitiligo
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.
Detailed Description
the study is to evaluate the efficacy of NB-UVB, latanoprost, and combination of them on the TWEAK serum level in patients with non-segmental vitiligo.
Eligibility Criteria
Inclusion
- Patients with non-segmental vitiligo of any age and gender.
Exclusion
- History of vitiligo treatment with topical, systemic or biological agents prior to the study for at least 3 weeks.
- Pregnancy and lactation.
- Infections
- Patients with other autoimmune diseases.
- Patients with chronic diseases: cardiac diseases, hepatic disorders, hematologic disease, chronic renal failure or malignancies.
Key Trial Info
Start Date :
January 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 13 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04811326
Start Date
January 13 2021
End Date
March 13 2024
Last Update
August 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
faculty of medicine, Aswan University
Aswān, Aswan Governorate, Egypt, 81528